Newsbenzinga
What's Going On With Fulcrum Therapeutics Stock On Thursday?
· Published
Article summary
Fulcrum Therapeutics halts pociredir development after FDA concerns over malignancy risk and begins a strategic review.
An excerpt from the original article.
Comments —
Loading comments…